Receives $250K Investment from the Alzheimer's Drug Discovery Foundation (ADDF) to Advance First-in-Class Circular RNA Blood-Based Biomarker Tests for the Early Detection of AD
Summary
Circular Genomics received a $250,000 investment from the Alzheimer's Drug Discovery Foundation through its Diagnostics Accelerator program. The funding will support further study of circular RNA blood-based biomarkers for detecting Alzheimer's disease and tracking its progression. Circular Genomics is working to develop first-in-class blood tests that improve diagnosis and patient stratification for neurological and psychiatric conditions. The company is collaborating with Washington University Medicine to validate the biomarkers and distinguish Alzheimer's from other dementias.
Funding
Amount
$250.0K
Total raised
Date
July 8, 2025
Announcement date
Investors
Washington University in St. Louis, Alzheimer's Drug Discovery Foundation Diagnostics Accelerator
Lead investors
Company
circulargenomics.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected